最新刊期
卷 27 ， 期 7 ， 2017
-
-
-
- 摘要：Background and purpose: Placental site trophoblastic tumor (PSTT) is a special type of gestational trophoblastic tumor. It remains no general cell line for PSTT. The aim of this study was to establish and identify a human PSTT cell line. Methods: In this study, a PSTT cell line (PSTT-1) was derived from primary culture of a surgically resected PSTT tissue. We further identified the basic characteristics of PSTT-1, including cell morphology, cell growth curve, karyotype analysis, short tandem repeat (STR) profiling of PSTT-1 and its parental tumor, and immunohistochemistry analysis. Results: A human PSTT cell line named PSTT-1 was successfully established. PSTT-1 formed a monolayer growth and lost contact inhibition, and exhibited a pleomorphic morphology. PSTT-1 cells grew actively in vitro. PSTT-1 was passaged every 5 days, and maintained in culture for more than 30 passages. Karyotyping of PSTT-1 revealed normal female karyotype: 46, XX. STR profiling of PSTT-1 was nearly identical to its parental tumor. Immunohistochemistry analysis of PSTT-1 revealed expression of β-catenin, CD146, human chorionic gonadotropin (hCG), human placental lactogen (hPL) and Muc4. Conclusion: This study established a PSTT cell line, which could be useful for further research on PSTT.关键词：Placental site trophoblastic tumor;Cell line;Primary culture2|1915|0更新时间：2025-12-31
- 摘要：Background and purpose: The transmembrane adaptor Csk-binding protein (CBP), a recently identified tyrosine kinase of the Src family, is implicated in various aspects of cancer cell biology. This study aimed to investigate the effect of the transmembrane protein CBP on the proliferation and apoptosis ability of A431 cells of human cutaneous squamous cell carcinoma and the implicated molecular mechanism. Methods: The CBP-EGFP lentiviral vector was constructed. A431 cells were transfected with CBP-EGFP lentiviral vector or negative-EGFP lentiviral vector, or remained untransfected. The transfection efficiency was detected by laser confocal microscope. After additional culture, the proliferation potential of A431 cells was assayed with CCK-8, and the apoptotic rate was assessed by flow cytometry (FCM). Lck, Csk and Fyn mRNA levels were detected by real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) and their protein levels by Western blot. Results: The A431 cell line with overexpression of PAG was constructed successfully. CCK-8 results suggested that overexpression of CBP markedly inhibited cell growth, with statistically significant differences at 2-6 days between the groups (P<0.05). FCM showed that both the apoptotic rate and the death rate of the cells transfected with CBP-EGFP lentiviral vector were increased significantly compared to those of the cells transfected with negative-EGFP lentiviral vector or untransfected cells (P<0.001). RTFQ-PCR results showed that the Lck mRNA relative expression level of the cells transfected with CBP-EGFP lentiviral vector was significantly reduced (P<0.001), but Csk and Fyn mRNA expression levels were 1.6 times and 3.8 times as high as the untransfected cells, respectively (P<0.001). Western blot results showed that the Lck protein level was significantly decreased after transfection with CBP-EGFP lentiviral vector (P<0.001), whereas the Csk and Fyn protein levels were significantly increased (P<0.001). Conclusion: The ectopic expression of CBP might inhibit the proliferation or growth of A431 cells, induce cell apoptosis and accelerate cell death, which may be related to down-regulation of Lck and up-regulation of Csk and Fyn expression.关键词：cutaneous squamous cell carcinoma;Csk-binding protein;Proliferation;Apoptosis2|2199|0更新时间：2025-12-31
- 摘要：Background and purpose: The incidence of BRAF mutation ranged from 5% to 15% among colorectal cancer according to previous studies, and was associated with poor survival. To evaluate safety, feasibilityand efficiency of BRAF inhibitor combined with epidermal growth factor receptor (EGFR) inhibitor for patient-derived xenografts (PDXs) of BRAF mutant recurrent and metastatic colorectal cancer. Methods: From Jan. 2016 to Dec. 2016, a total of 34 colorectal cancer patients were performed CT guided biopsy because of recurrence or metastasis indicated by image examination. PDXs models of recurrent and metastatic colorectal cancer were established by biopsy specimen. Screened the BRAF V600E mutant and cultivated to F2 generation for drug administration. The experimental group: BRAF inhibitor (Group A), EGFR inhibitor (Group B), BRAF and EGFR inhibitor (Group C). The control group: placebo (Group D). After three weeks, the efficiency was evaluated by tumor inhibition rate. Results: Twenty-three of the patients were confirmed recurrence or metastasis by pathology. Sixteen PDXs models were established, with success rate of 69.6% (16/23). Four BRAF V600E mutant patients were screened and PDXs models were established. There was no obvious drug toxicity related death in experimental group. The tumor inhibition rate of experimental group was 21.57%、21.61% and 66.81%, respectively. Group C had the most significant reduction of tumor volume (P<0.05). Conclusion: Combination of BRAF and EGFR inhibitor had high safety, feasibility and efficiency in PDXs of BRAF mutant recurrent and metastatic colorectal cancer.关键词：Colorectal cancer;Recurrence and metastasis;BRAFmutation;Patient-derived xenografts model2|2364|0更新时间：2025-12-31
- 摘要：Background and purpose: The key component of the hematopoietic microenvironment is bone marrow stromal cells (BMSC). Several studies have provided evidence suggesting that proliferation, survival, and drug resistance of AML can be modulated by BMSC within the bone marrow hematopoietic microenvironment. Therefore, in addition to therapies that directly target acute myelogenous leukemia (AML), interruption of leukemia cell and BMSC interactions should be considered when designing anti-AML therapeutic strategies. Hedgehog (Hh) protein belongs to a family of secreted proteins, which is widely expressed in mammals and non-mammals species and involved in the regulation of a variety of tumor formation in mature organs, angiogenesis, stem cell differentiation, immune cells, and embryonic development. Hh signaling allows for the modulation of the microenvironment to prepare a tumor-suitable niche by manipulating tumor cell growth, differentiation, and immune regulation, thus creating an enabling environment for progression and metastasis. However, it remains unclear whether the bone marrow hematopoietic microenvironment contributes to the increased survival of HL-60 cells by Hh signaling. Therefore, we studied the influence of bone marrow stromal cell-induced Hh signaling on the survival of HL-60 cells. Methods: CCK-8 kit was used for the detection of HL-60 cell proliferation in different experimental groups. Annexin V-FITC/PI double staining was used to detect the HL-60 cell apoptotic rate. Semiquantitative reverse transcription polymerase chain reaction (SQRT-PCR) was used to detect the experimental group Hh signaling pathway components of GLI1 mRNA and BCL-2, BCL-XL expression. GLI1 apoptotic gene expression levels were measured using immunofluorescence assay. Results: Bone marrow stromal cells promote proliferation and inhibit apoptosis of HL-60 cells, and 10 μmol/L of GANT61 can reverse these effects of bone marrow stromal cells. In co-culture system of HL-60 cells, GLI1 protein and mRNA expression increased and apoptosis inhibiting gene expression of BCL-2 and BCL-XL mRNA were upregulated. Conclusion: Bone marrow stromal cells have a protective effect on acute myeloid leukemia cells. The mechanism may involve activation of the Hh signaling pathway in acute myeloid leukemia cells by bone marrow stromal cells leading to increased expression of downstream target gene BCL-2 and BCL-XL.关键词：Acute myelogenous leukemia;GANT61;Hedgehog-GLI signaling pathway2|1997|0更新时间：2025-12-31
- 摘要：Background and purpose: It is suggested that MUTYH mutation is closed to high colorectal cancer risk, but it is not clear that the relationship between MUTYH mutation and susceptibility to familiar breast carcinoma. The study was to investigate the significance of MUTYH c.892-2A>G splicing mutation in familial breast cancer. Methods: The mutations of MUTYH，BRCA1 and BRCA2 genes were tested by the next generation sequencing (NGS) method in total of 224 participants， from 95 families with breast cancer patients (containing breast cancer patients and their relatives), and then comparisons were carried out between them. The mutations detected by NGS were verified by Sanger sequencing. Results: Seven participants from 4 families had a MUTYH c.892-2A>G splicing mutation, with a mutation rate of 3.1% (7/224), of which only one proband carried with this mutation. In 224 participants, only one proband carried with BRCA1 mutation. While 9 participants from 5 families had BRCA2 mutations, and their mutation rate was 4% (9/224). Further the BRCA2 mutation site detected in the proband of every family was not the same. There were no significant differences between the number of MUTYH c.892-2A>G mutation and BRCA2 mutation or between the number of MUTYH c.892-2A>G mutation and BRCA 1 mutation. And there was no case which existed MUTYH and BRCAs gene co-mutations. Conclusion: Although its high mutation rate happens in the high-risk healthy population with a history of breast cancer, MUTYH c.892-2A>G is likely to be a low penetrance gene mutation of susceptibility to breast cancer.关键词：MUTYH;Familial breast cancer;BRCA1;BRCA22|2562|0更新时间：2025-12-31
- 摘要：Background and purpose: Cervical cancer is the fourth most common cancer in females worldwide. In recent years, the morbidity and mortality are rising in China. The continued infection with high-risk human papillomavirus (hrHPV) is closely related to the invasive cervical carcinoma (ICC) and the precancerous lesions. The application of HPV prophylactic vaccine has become an effective measure for the prevention of cervical cancer. This study aimed at providing more evidence for the estimation of the potential impact of 9-valent HPV vaccine, by analyzing the distribution of 7 hrHPV types (HPV16/18/31/33/45/52/58), included in the vaccine, in histologyconfirmed ICCs and precancerous lesions from local women. Methods: Cervical samples with histology follow-up from Fudan University Shanghai Cancer Center were collected for HPV genotyping by polymerase chain reaction-reverse dot blot (PCR-RDB). Relative contribution of HPV types in ICCs and precancerous lesions was expressed as the percentages of type-specific cases among HPV-positive cases. Multiple infections were incorporated into single infection using the method of proportional weighting attribution (PWA). Results: A total of 624 cases were obtained, including 117 cases of negative for intraepithelial lesion or malignancy (NILM), 45 low-grade squamous intraepithelial lesion (LSIL), 268 high-grade squamous intraepithelial lesion (HSIL) and 194 ICC. The HPV prevalences of all, and of LSIL, HSIL and ICC were 84.29%, 71.11%，95.90% and 91.75%, respectively. The PWA of HPV 16/18 to LSIL, HSIL and ICC were 50.00%, 70.44% and 91.71%, whereas the attribution of HPV16/18/31/33/45/52/58 to LSIL, HSIL and ICC were increased to 86.34%，98.61% and 94.89%, respectively. The addition of 5 hrHPV types (HPV31/33/45/52/58) resulted in the reduction of relative contribution in LSIL, HSIL and ICC, as 36.34%, 28.17% and 3.18%, respectively. Conclusion: With the inclusion of additional 5 hrHPV types, the 9-valent HPV vaccine would likely prevent the occurrence of more ICC and precancerous lesions, and would especially benefit the prevention of LSIL and HSIL in China.关键词：Genotype;9-valent human papillomavirus vaccine;Squamous intraepithelial lesion;uterine cervical cancer2|4880|0更新时间：2025-12-31
- 摘要：Background and purpose: T cell immunoglobulin and mucin-domain-containing molecules 3 (Tim-3) plays a pivotal role in immune regulation. It participates in the occurrence and development of a variety of diseases, and Tim-3 is associated with immune escape and poor prognosis. The aim of this study was to investigate the expression of negative costimulatory molecule, Tim-3, in macrophages in non-small cell lung cancer (NSCLC) and explore the clinical significance of the expression. Methods: A total of 126 human lung cancer tissue specimens were obtained from pathologically confirmed and newly diagnosed NSCLC patients. The expression level of Tim-3 was analyzed by immunohistochemistry staining. Correlation analysis was performed to study the relationship between Tim-3 expression in macrophages and clinicopathological features. Survival analysis was performed by Kaplan-Meier. Results: Tim-3 was mainly expressed in the cytoplasm and cell membrane of macrophages. Tumor size, lymph node metastasis, TNM stage were significantly correlated with Tim-3 expression level (P=0.002, 0.045 and 0.022, respectively). Tim-3 expression in macrophages was negatively correlated with the prognosis of patients. Higher Tim-3 expression had a shorter overall survival (OS) in patients with stage Ⅲ NSCLC (χ2=12.910, P=0.000; Median OS: 80 months vs 32 months). Moreover, the expression level of Tim-3 had negative correlation with disease-free survival (DFS) in patients with stage Ⅲ NSCLC (χ2=6.135, P=0.013; Median DFS: 41 months vs 24 months). In addition, Tim-3 expression in lymphocytes was negatively correlated with OS and DFS in patients with stage Ⅲ NSCLC (χ2=4.737, P=0.030, Median OS: 80 months vs 47 months; χ2=5.882, P=0.015, Median DFS: 41 months vs 24 months). Conclusion: Tim-3, as a key negative regulator in anti-tumor immunity, contributes to the tumor immune evasion. It has an adverse influence on the prognosis of NSCLC patients.关键词：T cell immunoglobulin and mucin-domain-containing molecules 3;Non-small cell lung carcinoma;Macrophages;Prognosis2|1785|0更新时间：2025-12-31
- 摘要：Background and purpose: Long non-coding RNA (lncRNA) is associated with carcinogenesis and cancer development. LncRNA promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) was correlated with the progression and prognosis of various cancers. This study aimed to investigate the expression and clinical significance of PANDAR in non-small cell lung cancer (NSCLC). Methods: Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to detect PANDAR expression in 94 cases of NSCLC tissues and adjacent tissues. The association with patient clinic-pathological characteristics, diagnostic value and prognosis of PANDAR were further analyzed. Results: PANDAR expression was significantly downregulated in the NSCLC compared with adjacent tissues (P<0.001). There was significant differences between tumor size, lymphatic metastasis, TNM stage and histologic differentiation in terms of PANDAR expression (χ2=9.197, P=0.002 4; χ2=7.126, P=0.008; χ2=6.271, P=0.012; χ2=8.147, P=0.004). The area under the curve (AUC) of receiver operating characteristic (ROC) curve was 0.797 (95%CI: 0.614-0.849; P<0.001). The sensitivity and specificity were 49.8% and 84.3%, respectively. The index of Youden was 0.402. The differences between PANDAR low expression and high expression groups were statistically significant in overall survival time and progression free survival (χ2=7.282, P=0.007; χ2=6.777, P=0.009). Conclusion: The expression of PANDAR is down-regulated in patients with NSCLC and might prove useful as a biomarker for diagnosis and prognostic significance.关键词：Promoter of CDKN1A antisense DNA damage activated RNA;Non-small cell lung cancer;Receiver operating characteristic curve;Clinical pathological;Biomarker2|1556|0更新时间：2025-12-31
- 摘要：Background and purpose: Salivary gland myoepithelial carcinoma (MC) is a rare malignant salivary gland neoplasm, and its diagnosis and treatment remain controversial. This study aimed to discuss the clinical features, pathological manifestation, immunohistochemical phenotype and therapy in order to make progress in diagnosis and treatment of salivary gland MC. Methods: The clinical data of 12 cases of salivary gland MC from Jan. 2010 to Jun. 2016 were analyzed. The average age of the 12 cases was (48.9±12.2) years. Microscopic changes were analyzed after the sections were stained with routine H-E and immunohistochemical methods. 11 cases received radical surgery only, and 2 cases received postoperative radiotherapy. One case with incomplete resection was administered with 4 cycles of docetaxel+cisplatin chemotherapy regimen (120 mg docetaxel on day 1 and 40 mg cisplatin on days 1‑3, every 28 days). Results: Seven cases occurred in parotid glands and 5 occurred in minor salivary glands. The common size of MC was between 2 and 5 centimeters. Tumors in section appeared off white or grey pink, the capsules were intact, the boundaries were unclear, and necrosis and liquescence existed. Clear cells were predominant in MC, while epithelioid, plasmacytoid, and spindle cells also existed. Cell atypia was obvious and necrosis and liquescence were shown in 4 cases. CK, S-100, EMA, SMA, calponin, p63, Vim and Ki-67 were expressed in 12, 7, 7, 4, 8, 11, 5 and 9 cases, respectively. Ki-67 labelling index was 2%～40%, and 15% was the average. The follow-up time was 2-78 months. Local recurrence and metastasis were not detected in 10 cases who underwent extended resection, and 1 case died of renal myoepithelial carcinoma 5 months after operation. One case died 3 months after chemotherapy. Conclusion: The histological changes of myoepithelial carcinoma cells are diverse. Pathological methods and the immunohistochemical examination of CK, p63, Ki-67, S-100, Vim, calponin, EMA and SMA are helpful for improving the diagnosis rate. Surgery with tumour-free margins is the main treatment for myoepithelial carcinoma. Neck dissection is not necessary for the cases without local lymphatic metastasis.关键词：Myoepithelial carcinoma;Salivary gland;Diagnosis;Immunohistochemistry;Treatment2|3097|0更新时间：2025-12-31
- 摘要：Background and purpose: Primary renal lymphoma (PRL) is rare in clinic, difficult to diagnose preoperatively and easily misdiagnosed as renal cancer. We investigated the clinical pathological characteristics and treatment as well as prognosis of PRL.. Methods: Clinical data from 61 cases of PRL domestic case reports (1981—2014) were obtained and analysed retrospectively. Results: Of the 61 patients, 34 cases (55.7%) were men, 27 cases (44.3%) were women, the ratio was 1.3∶1.0. The age of onset was between 3 and 84 years with high incidence among patients aged 50 to 70 years, and the average age was 52.3 years. Unilateral lesions were found in 53 cases (86.9%), of which the left kidney in 34 cases (64.2%), 19 cases (35.8%) of the right kidney. Bilateral lesions were found in 8 cases (13.1%). The signs and symptoms of PRL included back pain in 45 cases (73.8%), fever in 17 cases (27.9%), hematuria in 8 cases (13.1%), acute renal failure in 2 cases (3.3%). There were 58 cases (95.1%) of non-Hodgkin’s lymphoma (NHL), accounting for the vast majority, of which B cell lymphoma (BCL) in 48 cases (82.6%), T cell lymphoma (TCL) in 5 cases (8.7%), not clear in 5 cases (8.7%). Diffuse large B-cell lymphoma (DLBCL) was the most common type (28 cases, 58.3%). A total of 47 cases (77.0%) underwent surgery, 48 cases (78.7%) received chemotherapy (14 cases of simple chemotherapy, 34 cases of postoperative adjuvant chemotherapy), 9 cases (14.8%) underwent radiotherapy. One case (1.6%) was lost to follow-up, and prognosis was not mentioned in 3 cases (4.9%). There were 34 cases (55.7%) in stable condition and survival, 23 cases (37.7%) had recurrence and progression, 4 cases (6.6%) achieved remission after retreatment, and 19 cases (31.1%) died at last. Conclusion: PRL is a rare tumor with higher malignancy, poorer prognosis as well as easy to misdiagnosis. Radical nephrectomy among patients with early-stage PLR combined with postoperative chemotherapy and other comprehensive treatment, could help to reduce recurrence and improve the prognosis of the disease.关键词：Kidney neoplasms;Lymphoma;Clinical characteristics;Retrospective studies2|2761|0更新时间：2025-12-31
- 摘要：Background and purpose: There is a lack of serum markers for the diagnosis of ovarian cancer currently. This study aimed to investigate the clinical significance of serum sialic acid (SA) levels in patients with ovarian cancer in auxiliary diagnosis and efficacy monitoring. Methods: Enzyme reaction method was used to analyze serum SA levels and chemiluminescence was employed to detect CA125 and HE4 in participants including 194 healthy controls, 332 patients with gynecological cancer and 230 patients with benign disease. Results: The serum SA levels in patients with gynecological cancer ［584.0 (499.8, 702.5) mg/L］ were higher than those in patients with benign disease ［497.0 (454.0, 559.0) mg/L］ and healthy controls ［475.0 (443.8, 505.0) mg/L, P<0.05］. The serum SA levels in patients with ovarian malignant tumors ［675.0 (582.0, 816.0) mg/L］ were the highest. The sensitivity of the combined detection of serum SA with CA125 for ovarian malignant tumors was up to 95.17%, and the negative predictive value was 94.37%. With the improvement of the condition, the serum concentration of SA in patients with ovarian cancer gradually decreased. Conclusion: The detection of serum SA can be applied to early screening, differential diagnosis and efficacy monitoring.关键词：Gynecological cancer;Ovarian cancer;Serum sialic acid;Enzyme reaction2|1911|0更新时间：2025-12-31
- 摘要：Leptomeningeal metastasis (LM) is a serious fatal complication of non-small cell lung cancer (NSCLC), which is lack of specificity in clinical manifestations. Symptoms and signs are classically divided into three domains of neurological function: cerebral hemisphere, cranial nerve and spinal cord, and exiting nerve roots. Apart from a clinical suspicion of LM, diagnosis is based on demonstration of cancer in cerebrospinal fluid or radiographic manifestations as revealed by neuraxis imaging. Although the novel agents including targeted therapies such as EGFR-TKIs have conferred a survival benefit in selected NSCLC patients in some studies, the prognosis is still poor. This review focuses on the pathologic physiology, clinical manifestations, diagnosis and therapies of LM in NSCLC.关键词：Non-small cell lung cancer;Leptomeningeal metastasis;Diagnosis;Therapy2|3173|0更新时间：2025-12-31
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
0